Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 64 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric CancerStatus unknownNCT04202601Phase 1/2
• Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung CancerStatus unknownNCT04201990Phase 1/2
• Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaCompletedNCT04201873Phase 1
• Pembrolizumab + Defactinib In Pleural MesotheliomaWithdrawnNCT04201145Phase 1
• A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial CarcinomaCompletedNCT04200963Phase 1
• A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid TumorsCompletedNCT04200404Phase 1/2
• Pembrolizumab With Axitinib in Recurrent Endometrial CancerWithdrawnNCT04197219Phase 2
• BDB001-102: Open Label Dose Escalation of BDB001 in Combination w AtezolizumabCompletedNCT04196530Phase 1
• Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal CancersActive, not recruitingNCT04196465Phase 2
• Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric CancerCompletedNCT04195828Phase 2
• Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBMActive, not recruitingNCT04195139Phase 2
• Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal CancerStatus unknownNCT04194359Phase 2
• A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)CompletedNCT04194203Phase 3
• Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical StudyStatus unknownNCT04190745Phase 2
• Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLCStatus unknownNCT04189094Phase 2
• HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck CancerCompletedNCT04188951Early Phase 1
• A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast CancerWithdrawnNCT04188119Phase 2
• LITT and Pembrolizumab in Recurrent Brain MetastasisTerminatedNCT04187872Phase 1
• A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Phase 3
• Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncerActive, not recruitingNCT04186013Phase 2
• A MolEcularly Guided Anti-Cancer Drug Off-Label TrialActive, not recruitingNCT04185831Phase 2
• Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTerminatedNCT04185311Phase 1
• Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaWithdrawnNCT04184518Phase 2
• KN035 in Patients With Advanced Multiple Primary TumorsStatus unknownNCT04182789Phase 2
• Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04182724Phase 1/2
• Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOSStatus unknownNCT04181489Phase 2
• Toripalimab in Combination With Axitinib in Patients With Localized Mucosal MelanomaStatus unknownNCT04180995Phase 2
• Atezolizumab Plus Bevacizumab With HCC and HBV InfectionActive, not recruitingNCT04180072Not applicable
• Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint InhibitorWithdrawnNCT04179110Phase 2
• Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal CancerStatus unknownNCT04179084Phase 2
• Nivolumab with Chemotherapy in Pleural Mesothelioma After SurgeryCompletedNCT04177953Phase 2
• Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal CancerStatus unknownNCT04177875Phase 2
• Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04177797Phase 2
• A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC PatientsCompletedNCT04177290Phase 1
• Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCCStatus unknownNCT04174781Phase 2
• PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric CancerStatus unknownNCT04174339Not applicable
• Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung CancerTerminatedNCT04173325Phase 1
• Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue SarcomaCompletedNCT04172805Phase 2
• A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)CompletedNCT04172571Phase 2
• A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid TumorsCompletedNCT04172506Phase 1/2
• Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid TumorsCompletedNCT04172454Phase 1/2
• NGS as the First-line Treatment in Advanced Biliary Tract CancerCompletedNCT04172402Phase 2
• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 2
• Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)CompletedNCT04170556Phase 1/2
• Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic MetastasisStatus unknownNCT04170179Phase 2
• Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib TreatmentActive, not recruitingNCT04169841Phase 2
• Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTTStatus unknownNCT04169399Phase 2
• A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLCStatus unknownNCT04167774Phase 2
• SinTilimab After Radiation (STAR Study)CompletedNCT04167657Phase 2
• Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)Status unknownNCT04167293Phase 2/3
• WaKING: Wnt and checKpoint INhibition in Gastric CancerActive, not recruitingNCT04166721Phase 1/2
• Plasma-Adapted First-Line Pembro In NSCLCActive, not recruitingNCT04166487Phase 2
• Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast CancerActive, not recruitingNCT04165993Phase 2
• Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerStatus unknownNCT04164745Phase 2
• Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC PatientsStatus unknownNCT04164238Phase 2
• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedNCT04164199Phase 3
• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerActive, not recruitingNCT04164082Phase 2
• Combined Immunotherapy and Targeted Therapy for Advanced Liver CancerStatus unknownNCT04163237Phase 3
• A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid TumorCompletedNCT04162327Phase 1
• A Study of Nivolumab and Chemotherapy Followed by Surgery for MesotheliomaActive, not recruitingNCT04162015Phase 1
• RICE: Radio-Immuno-Chemotherapy of Cancer of the EsophagusActive, not recruitingNCT04159974Phase 2
• Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal CarcinomaActive, not recruitingNCT04156698Phase 2
• A Study in Subjects With Advanced Solid TumorsTerminatedNCT04156100Phase 1
• Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic CancerCompletedNCT04156087Phase 2
• Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLCStatus unknownNCT04153734Phase 2
• A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric CancerStatus unknownNCT04152889Phase 2
• A Safety Study of LY3462817 and LY3509754 in Participants With PsoriasisTerminatedNCT04152382Phase 1
• A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnNCT04151563Phase 1/2
• Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGITTerminatedNCT04150965Phase 1/2
• A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard ChemotherapyStatus unknownNCT04150575Phase 2
• Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaWithdrawnNCT04149275Phase 2
• A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.CompletedNCT04147351Phase 2
• Sintilimab in FH-deficient Renal Cell CarcinomaStatus unknownNCT04146831Phase 2
• SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownNCT04146402Phase 3
• Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell CarcinomaStatus unknownNCT04146181Phase 2
• Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRCWithdrawnNCT04145193Phase 2
• A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenActive, not recruitingNCT04145115Phase 2
• Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLCCompletedNCT04144608Phase 2
• Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid TumorsStatus unknownNCT04142931Phase 1
• Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCActive, not recruitingNCT04141644Phase 1
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/2
• Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsActive, not recruitingNCT04140500Phase 1/2
• Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaStatus unknownNCT04140318Phase 2
• A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerStatus unknownNCT04139135Phase 3
• Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical CystectomyActive, not recruitingNCT04138628Phase 2
• A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid TumorsCompletedNCT04135261Phase 1
• Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT04134325Early Phase 1
• Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.Status unknownNCT04134182Phase 2
• Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)Active, not recruitingNCT04134000Phase 1
• Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaCompletedNCT04133948Phase 1/2
• Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLCStatus unknownNCT04133337Phase 1/2
• A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadCompletedNCT04132817Phase 1
• Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabActive, not recruitingNCT04130516Phase 1/2
• NovoTTF-200A + Pembrolizumab In Melanoma Brain MetastasisWithdrawnNCT04129515Phase 1/2
• Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT04129320Phase 2/3
• Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk MyelodysplasiaWithdrawnNCT04128020Phase 1
• Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal TypeActive, not recruitingNCT04127227Phase 2
• Study of SHR-1210 Combined With Apatinib in the Treatment of SarcomaStatus unknownNCT04126993Phase 2
• High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)Status unknownNCT04126460Phase 2
• PVSRIPO in Combination With Nivolumab in MelanomaWithdrawnNCT04125719Phase 1

← Immune Checkpoint Inhibitors overview